FDA slams clinical hold on tiny psychedelics player’s shot at bringing LSD-assisted therapy to more patients
…facing a holdup at the FDA in bringing its LSD program to more patients… didn’t dive into what issues the agency flagged before it made its decision. Not a whole lot is known about the New York biotech except that Barrow, formerly interim CEO and chief development officer, stepped into the full-time CEO role about…
Recent Comments